Home Search

dbv - search results

If you're not happy with the results, please do another search
Viaskin-Patch-Delay

FDA Has Questions About Viaskin Peanut Efficacy, Delays Meeting with DBV Technologies

0
The company warned the FDA's target date for their decision on approval could be delayed.
Viaskin Peanut

DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III Open-Label Extension Study...

Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
Viaskin Peanut

DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment...

If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.
Viaskin Patch

DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut for the Treatment...

This submission addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December.
Viaskin Peanut

DBV to Resubmit Application to FDA for Viaskin Peanut Approval in Q3 2019

Company allays concerns that BLA would not be resubmitted.
Viaskin Peanut

DBV Withdraws FDA Application for Viaskin Peanut with Plan to Resubmit

0
The company believes the additional information needed to support this filing is available without further clinical studies.
Viaskin Peanut

DBV Applies for FDA License to Sell Viaskin Peanut Patch Therapy

"This submission represents a significant step forward for those families living with peanut allergy."
DBV Patch Closeup

DBV Completes Phase III Study of Peanut Patch

0
The phase III trial was designed to assess the safety and routine clinical use of Viaskin Peanut.

Nestlé Partners with DBV to Develop Milk Allergy Test

0
The world's largest food business forays into allergy diagnostic services to help sell infant formula.
Viaskin Patch

Viaskin Milk Results Shows Potential for Treatment of Milk Allergy in Children

0
95.5% of the participants completed treatment, with most adverse effects being mild or moderate reactions at the application site.